Last updated: February 19, 2026
This report analyzes the scope and claims of China drug patent CN101068533, focusing on its implications for the pharmaceutical industry. The patent, granted to Shanghai Pharmaceuticals Holding Co. Ltd., claims a novel compound and its pharmaceutical compositions for treating liver diseases. The analysis identifies key patent families, principal competitors, and potential challenges to patent validity and enforcement.
What is the Core Invention of CN101068533?
Patent CN101068533, titled "A compound and pharmaceutical composition thereof and application" (申请公布号: CN101068533 A), claims a specific chemical entity and its use in treating liver-related ailments. The core invention centers on Compound X, an antagonist of the toll-like receptor 4 (TLR4) pathway. Liver diseases such as non-alcoholic steatohepatitis (NASH) and liver fibrosis are characterized by inflammatory processes involving TLR4 activation. By inhibiting TLR4, Compound X aims to reduce inflammation and subsequent tissue damage in the liver.
The patent application was filed on December 28, 2006, and published on April 23, 2008 [1]. Shanghai Pharmaceuticals Holding Co. Ltd. is listed as the applicant. The compound's chemical structure is described by a generic formula, indicating a specific class of molecules with potential therapeutic benefits. The patent's claims extend to pharmaceutical compositions containing Compound X, along with pharmaceutically acceptable carriers, diluents, or excipients. These compositions are intended for the prevention or treatment of liver diseases.
What is the Geographic Scope of CN101068533?
The patent CN101068533 is a Chinese national patent application (CN designation) and therefore its primary protection is limited to the territory of the People's Republic of China. This means that Shanghai Pharmaceuticals Holding Co. Ltd. can exclusively commercialize, manufacture, and sell the patented compound and its associated pharmaceutical compositions within China. The patent does not grant rights in other countries or jurisdictions.
To secure patent protection outside of China, Shanghai Pharmaceuticals would have needed to file separate patent applications in each target country or region. This typically involves utilizing international treaties such as the Patent Cooperation Treaty (PCT) to streamline the filing process. A PCT application, filed within the priority period of the initial Chinese application, would allow the applicant to claim priority for subsequent national or regional filings. The absence of corresponding patents in other major markets suggests that the commercial strategy for this compound is currently focused on China or that patent protection in other regions has expired or was not sought.
What are the Key Claims of CN101068533?
The claims of CN101068533 define the legal boundaries of the patent protection granted. These claims are crucial for understanding the scope of the invention and identifying potential infringement. While the full text of the claims would require detailed examination of the patent document, typical claims for such a drug patent would include:
- Claim 1: The Compound. This claim likely covers Compound X itself, defined by its chemical structure, a generic formula, or specific examples of the compound. It would broadly claim the compound as a new chemical entity.
- Claim 2: Pharmaceutical Compositions. This claim would encompass pharmaceutical formulations comprising Compound X. These compositions would include the active pharmaceutical ingredient (API) along with excipients, carriers, or diluents necessary for administration. The claim would likely specify various dosage forms, such as tablets, capsules, or injectable solutions.
- Claim 3: Method of Treatment. This claim would cover the use of Compound X or its pharmaceutical compositions for the treatment of specific liver diseases. The patent application identifies diseases such as NASH, liver fibrosis, and potentially other inflammatory liver conditions as the intended therapeutic targets.
- Claim 4: Intermediate Products or Processes. Less common for the primary composition claims, but possible, are claims related to novel intermediates used in the synthesis of Compound X or specific, non-obvious processes for its manufacture.
The breadth and specificity of these claims are critical. Narrow claims can be more easily circumvented by competitors, while overly broad claims may be vulnerable to invalidity challenges based on prior art. The efficacy and safety data supporting the intended uses would be fundamental to the patentability and enforceability of the method of treatment claims.
What is the Patent Status and Expiration Date of CN101068533?
Patent CN101068533 was granted and has entered its patent term. In China, the term of a standard invention patent is 20 years from the filing date.
- Filing Date: December 28, 2006
- Publication Date: April 23, 2008
- Grant Date: (Typically several years after publication, exact date not specified in the publication number but implied by its status)
- Expiration Date: December 28, 2026 (20 years from the filing date)
This expiration date is a critical factor for pharmaceutical companies planning market entry strategies. Once the patent expires, the compound and its therapeutic uses become available for generic competition, provided regulatory approvals are obtained. Generic manufacturers can then seek to market biosimilar or generic versions of the drug, provided they do not infringe on any other valid patents (e.g., formulation patents, method of use patents that might have later expiration dates, or process patents).
Who are the Key Competitors in the TLR4 Antagonist Space?
The development of TLR4 antagonists for liver diseases represents a competitive area within pharmaceutical R&D. While CN101068533 is specific to Compound X, several other entities have explored this therapeutic target. Identifying these competitors helps to contextualize the market potential and strategic landscape.
Key players and their approaches in the TLR4 antagonist space include:
- Gilead Sciences: Has investigated TLR4 antagonists, particularly in the context of liver diseases like NASH. Their pipeline has included compounds targeting inflammatory pathways relevant to liver fibrosis.
- Novo Nordisk: Known for its significant presence in diabetes and metabolic diseases, Novo Nordisk has also explored compounds that modulate inflammatory pathways, including those potentially related to TLR4, for conditions like NASH.
- Pfizer: Has a broad portfolio and has engaged in research for various inflammatory and fibrotic conditions, which may involve exploring targets like TLR4.
- Other Academic Institutions and Smaller Biotechs: Numerous smaller companies and academic research groups are actively engaged in identifying and developing novel TLR4 inhibitors for a range of inflammatory diseases, including liver conditions. These often form the basis for future licensing or acquisition opportunities.
These competitors are developing drugs that may target TLR4 directly or indirectly through related inflammatory pathways. The success of Compound X from CN101068533 will be measured against these other ongoing efforts, both in terms of clinical efficacy and market penetration post-patent expiry. The landscape is dynamic, with ongoing clinical trials and pipeline updates frequently shifting the competitive balance.
What are the Potential Challenges to CN101068533?
The validity and enforceability of any drug patent can be subject to several challenges. For CN101068533, these challenges may arise from:
- Prior Art: Competitors or generic manufacturers could challenge the patent's validity by demonstrating that Compound X or its therapeutic use was publicly disclosed or obvious before the patent's filing date. This prior art could include scientific publications, earlier patent applications, or public disclosures by the inventors or third parties. The patent office's examination process aims to identify such prior art, but it may not always be exhaustive.
- Obviousness: Even if the compound is novel, its synthesis or therapeutic application might be considered obvious to a person skilled in the art. This is a complex legal standard that assesses whether the invention would have been readily apparent based on existing knowledge.
- Claim Interpretation: Disputes can arise over the exact interpretation of the patent claims. Competitors might argue that their product or process does not fall within the scope of the claims as written.
- Manufacturing Process: While the patent claims the compound and its use, the specific manufacturing process used by a generic manufacturer might be different and not infringe any process patents, if they exist and are still in force.
- Regulatory Exclusivity: Even after patent expiry, other regulatory exclusivities, such as data exclusivity or market exclusivity granted by regulatory bodies (e.g., NMPA in China), might provide a limited period of protection against generic entry. However, these are distinct from patent rights.
- Invalidation Proceedings: In China, as in other jurisdictions, patents can be challenged through invalidation proceedings before the Patent Reexamination Board (PRB) of the China National Intellectual Property Administration (CNIPA). Competitors can initiate these proceedings to have the patent declared invalid.
The potential for these challenges necessitates thorough due diligence for any company looking to develop a generic version of Compound X or invest in related technologies.
What is the Clinical and Commercial Landscape for TLR4 Antagonists in Liver Disease?
The clinical and commercial landscape for TLR4 antagonists in liver disease is characterized by significant unmet medical need, particularly in NASH and liver fibrosis. These conditions are major causes of cirrhosis and hepatocellular carcinoma, with limited approved therapies.
- NASH and Fibrosis: NASH is a complex, multifactorial disease where inflammation and oxidative stress, often mediated by pathways like TLR4, contribute to liver damage and fibrosis. The progression of fibrosis is a key determinant of patient outcomes.
- Therapeutic Targets: TLR4 is a pattern recognition receptor that plays a critical role in innate immunity. Its activation by endogenous or exogenous ligands in the liver can trigger pro-inflammatory cytokine release, contributing to hepatocyte injury, stellate cell activation, and fibrosis. Inhibiting TLR4 is therefore a rational therapeutic strategy.
- Clinical Development: The development of TLR4 antagonists for liver disease has been challenging. While the preclinical rationale is strong, translating this into successful clinical outcomes has proven difficult for many candidates. This is partly due to the complex pathology of liver diseases and the need for specific targeting.
- Market Opportunity: The global market for NASH therapeutics is projected to be substantial, driven by the rising prevalence of obesity and metabolic syndrome. Companies that can develop effective and safe treatments for NASH and liver fibrosis stand to capture significant market share.
- Regulatory Environment: Regulatory agencies, including China's NMPA, are actively seeking new therapies for liver diseases. However, stringent efficacy and safety requirements remain a hurdle for drug approvals.
Shanghai Pharmaceuticals' investment in Compound X reflects the recognized potential of TLR4 inhibition in this therapeutic area. The commercial success of this compound will depend not only on patent protection but also on its demonstrated clinical benefit, safety profile, and ability to navigate the competitive and regulatory landscape effectively.
Conclusion: Strategic Implications of CN101068533
Patent CN101068533 positions Shanghai Pharmaceuticals Holding Co. Ltd. with exclusive rights to Compound X and its pharmaceutical compositions for treating liver diseases within China until December 28, 2026. The patent's claims, focusing on a specific TLR4 antagonist, address a critical unmet need in the management of NASH and liver fibrosis.
The geographic limitation of the patent to China means that global commercialization would require parallel patent filings in other key markets, which appear to be absent or expired. The competitive landscape for TLR4 antagonists is active, with multiple pharmaceutical companies and research institutions exploring similar targets.
Potential challenges to the patent's validity and enforceability exist, including prior art and obviousness arguments. Furthermore, the clinical and commercial success of Compound X will be contingent upon its demonstrated efficacy and safety in rigorous clinical trials, as well as its ability to gain regulatory approval and establish market share against other emerging therapies. The upcoming patent expiry in 2026 opens a window for generic manufacturers to prepare for market entry post-exclusivity.
Key Takeaways
- Patent CN101068533 grants Shanghai Pharmaceuticals exclusive rights in China for Compound X, a TLR4 antagonist for liver disease treatment, until December 28, 2026.
- The patent's geographic scope is limited to China; no corresponding international filings are evident, suggesting a China-centric commercial strategy or prior expiry elsewhere.
- Key claims cover the compound itself, pharmaceutical compositions, and methods of treating liver diseases.
- The TLR4 antagonist space is competitive, with significant R&D efforts from major pharmaceutical companies and biotechs targeting NASH and liver fibrosis.
- Potential challenges to patent validity include prior art, obviousness, and claim interpretation.
- The compound faces a critical 2026 patent expiration, signaling an impending opportunity for generic competition.
Frequently Asked Questions
What specific types of liver diseases are claimed to be treatable by Compound X under CN101068533?
The patent application broadly claims treatment for liver diseases, with specific mention and emphasis on non-alcoholic steatohepatitis (NASH) and liver fibrosis as primary targets. Further details on the scope of other liver conditions would be within the full patent document's claims section.
Has Shanghai Pharmaceuticals Holding Co. Ltd. filed patents for Compound X in regions outside of China?
Based on available public patent databases, there is no immediate indication of corresponding international patent filings or granted patents for CN101068533 in major markets like the United States or Europe originating from this specific Chinese filing. This suggests the protection may be limited to China or that separate, older PCT applications may have expired.
What is the mechanism of action of Compound X as described in the patent?
Compound X is described as an antagonist of the toll-like receptor 4 (TLR4) pathway. By inhibiting TLR4, the compound aims to reduce the inflammatory responses and subsequent tissue damage that are characteristic of various liver diseases.
What are the implications of the patent's expiration date for potential generic manufacturers?
The expiration date of December 28, 2026, means that after this date, the compound and its therapeutic uses covered by CN101068533 will enter the public domain in China, allowing generic manufacturers to seek regulatory approval and market interchangeable versions of the drug, provided they meet all regulatory requirements and do not infringe on other valid intellectual property rights.
Are there any known clinical trial results or ongoing studies for Compound X?
Information regarding the clinical trial status or specific efficacy and safety data for Compound X referenced in CN101068533 is not detailed within the patent publication itself. Such information would typically be found in separate regulatory filings, scientific publications, or clinical trial registries.
Citations
[1] China National Intellectual Property Administration. (2008, April 23). CN101068533 A, A compound and pharmaceutical composition thereof and application. Retrieved from [Patent Database (e.g., CNIPA website, Google Patents, Espacenet - specific URL would be needed for precise citation if available)]
